0000891293-19-000042.txt : 20190520
0000891293-19-000042.hdr.sgml : 20190520
20190520164126
ACCESSION NUMBER: 0000891293-19-000042
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190516
FILED AS OF DATE: 20190520
DATE AS OF CHANGE: 20190520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Craig Adam R
CENTRAL INDEX KEY: 0001339498
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 19839338
MAIL ADDRESS:
STREET 1: C/O INNOVIVE PHARMACEUTICALS, INC.
STREET 2: 555 MADISON AVENUE, 25TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2019-05-16
0
0000891293
CTI BIOPHARMA CORP
ctic
0001339498
Craig Adam R
C/O CTI BIOPHARMA CORP.
3101 WESTERN AVE., SUITE 800
SEATTLE
WA
98121
1
1
0
0
President and CEO
Non-Qualified Stock Option (right to buy)
0.8411
2019-05-16
4
A
0
1300000
0
A
2029-05-16
Common Stock
1300000
1300000
D
One-third of the shares underlying the option will vest on February 19, 2020, and one-third of the shares underlying the option will vest annually thereafter, such that all of the shares subject to the option will be vested and exercisable on February 19, 2022, subject to Dr. Craig continuing to be an employee or a service provider through each such date.
Bruce J. Seeley, Attorney-in-fact For: Adam R. Craig
2019-05-20